SELLAS Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial

SELLAS Life Sciences said on Nov. 17 that its cancer vaccine galinpepimut-S, or GPS, helped people with acute myeloid leukemia (AML) live longer in a pivotal phase 3 trial. The New York company now plans to meet the FDA about a filing.
What happened
The REGAL trial tested GPS on its own as maintenance therapy. Patients had AML that had reached a second or later remission after salvage treatment. When they enrolled, none were eligible for, or able to undergo, a donor stem cell transplant.
The trial randomized 126 patients one to one to GPS or to their doctor's choice of best available treatment. That control arm could mean observation, a hypomethylating agent, venetoclax or low-dose cytarabine.
- Survival: median overall survival was 24.0 months with GPS, compared with 14.7 months in the control arm.
- Risk of death: the company reported a 41% lower risk of death, a hazard ratio of 0.59, with a two-sided p-value of 0.035.
- Timing: the analysis ran after 80 deaths, as the trial's statistical plan set out.
- Safety: SELLAS said side effects were mostly mild to moderate, most often reactions at the injection site, with no new safety signals.
Chief executive Angelos Stergiou said the trial met its main goal and called the survival gain clinically meaningful for patients with very few options.
Why it matters
GPS is an off-the-shelf vaccine built from four peptides of the WT1 protein. It is meant to train T cells to attack leftover cancer cells that carry WT1. SELLAS licenses it from Memorial Sloan Kettering.
The trial's steering committee said these patients have poor survival and need new treatments. SELLAS described the data as phase 3 validation of its WT1 approach.
There are limits. These are topline results that have not been peer reviewed. BioPharm International noted that the trial was open label and that the control arm mixed several options, including observation. The release also gave no confidence interval for the hazard ratio. Secondary results, such as leukemia-free survival and measurable residual disease, are still being analyzed.
What it means for people in the industry
SELLAS plans to meet the FDA to discuss an accelerated filing strategy. It is preparing a biologics license application (BLA) for submission in the first half of 2027. Full results will go to a medical conference and a peer-reviewed journal.
SELLAS is a late-stage company. Besides GPS, it is developing SLS009, a CDK9 inhibitor. Things to watch include the outcome of the FDA meeting and the full secondary data. The release did not mention hiring.
This article is news only and is not medical advice.
See open pharma jobs in the US and Canada
Sources
- SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia, SELLAS Life Sciences press release (GlobeNewswire)
- SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial, BioPharm International
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.